Greengard O, Poltoratskaia N, Leikina E, Zimmerberg J, Moscona A
Department of Pediatrics, Mount Sinai School of Medicine, New York, New York 10029, USA.
J Virol. 2000 Dec;74(23):11108-14. doi: 10.1128/jvi.74.23.11108-11114.2000.
4-GU-DANA (zanamivir) (as well as DANA and 4-AM-DANA) was found to inhibit the neuraminidase activity of human parainfluenza virus type 3 (HPF3). The viral neuraminidase activity is attributable to hemagglutinin-neuraminidase (HN), an envelope protein essential for viral attachment and for fusion mediated by the other envelope protein, F. While there is no evidence that HN's neuraminidase activity is essential for receptor binding and syncytium formation, we found that 4-GU-DANA prevented hemadsorption and fusion of persistently infected cells with uninfected cells. In plaque assays, 4-GU-DANA reduced the number (but not the area) of plaques if present only during the adsorption period and reduced plaque area (but not number) if added only after the 90-min adsorption period. 4-GU-DANA also reduced the area of plaques formed by a neuraminidase-deficient variant, confirming that its interference with cell-cell fusion is unrelated to inhibition of neuraminidase activity. The order-of-magnitude lower 50% inhibitory concentrations of 4-GU-DANA (and also DANA and 4-AM-DANA) for plaque area reduction and for inhibition in the fusion assay than for reducing plaque number or blocking hemadsorption indicate the particular efficacy of these sialic acid analogs in interfering with cell-cell fusion. In cell lines expressing influenza virus hemagglutinin (HA) as the only viral protein, we found that 4-GU-DANA had no effect on hemadsorption but did inhibit HA2b-red blood cell fusion, as judged by both lipid mixing and content mixing. Thus, 4-GU-DANA can interfere with both influenza virus- and HPF3-mediated fusion. The results indicate that (i) in HPF3, 4-GU-DANA and its analogs have an affinity not only for the neuraminidase active site of HN but also for sites important for receptor binding and cell fusion and (ii) sialic acid-based inhibitors of influenza virus neuraminidase can also exert a direct, negative effect on the fusogenic function of the other envelope protein, HA.
4-GU-DANA(扎那米韦)(以及DANA和4-AM-DANA)被发现可抑制人副流感病毒3型(HPF3)的神经氨酸酶活性。病毒神经氨酸酶活性归因于血凝素神经氨酸酶(HN),它是一种包膜蛋白,对于病毒附着以及由另一种包膜蛋白F介导的融合至关重要。虽然没有证据表明HN的神经氨酸酶活性对于受体结合和多核体形成至关重要,但我们发现4-GU-DANA可阻止持续感染细胞与未感染细胞的血细胞吸附和融合。在蚀斑试验中,如果4-GU-DANA仅在吸附期存在,则会减少蚀斑数量(但不减少面积);如果仅在90分钟吸附期后添加,则会减少蚀斑面积(但不减少数量)。4-GU-DANA还减少了由神经氨酸酶缺陷变体形成的蚀斑面积,证实其对细胞间融合的干扰与神经氨酸酶活性的抑制无关。4-GU-DANA(以及DANA和4-AM-DANA)降低蚀斑面积和融合试验中抑制作用的50%抑制浓度比减少蚀斑数量或阻断血细胞吸附的浓度低一个数量级,这表明这些唾液酸类似物在干扰细胞间融合方面具有特殊功效。在仅表达流感病毒血凝素(HA)作为唯一病毒蛋白的细胞系中,我们发现4-GU-DANA对血细胞吸附没有影响,但通过脂质混合和内容物混合判断,它确实抑制了HA2b与红细胞的融合。因此,4-GU-DANA可干扰流感病毒和HPF3介导 的融合。结果表明:(i)在HPF3中,4-GU-DANA及其类似物不仅对HN的神经氨酸酶活性位点有亲和力,而且对受体结合和细胞融合的重要位点也有亲和力;(ii)基于唾液酸的流感病毒神经氨酸酶抑制剂也可对另一种包膜蛋白HA的融合功能产生直接负面影响。